These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30337279)

  • 1. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers.
    Moreira D; Adamus T; Zhao X; Su YL; Zhang Z; White SV; Swiderski P; Lu X; DePinho RA; Pal SK; Kortylewski M
    Clin Cancer Res; 2018 Dec; 24(23):5948-5962. PubMed ID: 30337279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.
    Kortylewski M; Moreira D
    Cancer Immunol Immunother; 2017 Aug; 66(8):979-988. PubMed ID: 28214929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.
    Zhao X; Zhang Z; Moreira D; Su YL; Won H; Adamus T; Dong Z; Liang Y; Yin HH; Swiderski P; Pillai RK; Kwak L; Forman S; Kortylewski M
    Mol Ther; 2018 Mar; 26(3):695-707. PubMed ID: 29433938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.
    Hossain DM; Dos Santos C; Zhang Q; Kozlowska A; Liu H; Gao C; Moreira D; Swiderski P; Jozwiak A; Kline J; Forman S; Bhatia R; Kuo YH; Kortylewski M
    Blood; 2014 Jan; 123(1):15-25. PubMed ID: 24169824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
    Hossain DM; Pal SK; Moreira D; Duttagupta P; Zhang Q; Won H; Jones J; D'Apuzzo M; Forman S; Kortylewski M
    Clin Cancer Res; 2015 Aug; 21(16):3771-82. PubMed ID: 25967142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.
    Alcantara MB; Tang WS; Wang D; Kaniowski D; Kang E; Dizman N; Chehrazi-Raffle A; Meza L; Zengin Z; Hall J; Hsu J; Egelston C; Moreira D; Horsager A; Pal SK; Kortylewski M
    Front Immunol; 2023; 14():1274781. PubMed ID: 38259453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.
    Zhang Q; Hossain DM; Duttagupta P; Moreira D; Zhao X; Won H; Buettner R; Nechaev S; Majka M; Zhang B; Cai Q; Swiderski P; Kuo YH; Forman S; Marcucci G; Kortylewski M
    Blood; 2016 Mar; 127(13):1687-700. PubMed ID: 26796361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TLR9 expression and secretion of LIF by prostate cancer cells stimulates accumulation and activity of polymorphonuclear MDSCs.
    Won H; Moreira D; Gao C; Duttagupta P; Zhao X; Manuel E; Diamond D; Yuan YC; Liu Z; Jones J; D'Apuzzo M; Pal S; Kortylewski M
    J Leukoc Biol; 2017 Aug; 102(2):423-436. PubMed ID: 28533357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
    Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
    J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
    Zhang Q; Hossain DM; Nechaev S; Kozlowska A; Zhang W; Liu Y; Kowolik CM; Swiderski P; Rossi JJ; Forman S; Pal S; Bhatia R; Raubitschek A; Yu H; Kortylewski M
    Blood; 2013 Feb; 121(8):1304-15. PubMed ID: 23287859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
    Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
    Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
    Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells.
    Adamus T; Hung CY; Yu C; Kang E; Hammad M; Flores L; Nechaev S; Zhang Q; Gonzaga JM; Muthaiyah K; Swiderski P; Aboody KS; Kortylewski M
    Mol Ther Nucleic Acids; 2022 Mar; 27():611-620. PubMed ID: 35036069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.
    Zoglmeier C; Bauer H; Noerenberg D; Wedekind G; Bittner P; Sandholzer N; Rapp M; Anz D; Endres S; Bourquin C
    Clin Cancer Res; 2011 Apr; 17(7):1765-75. PubMed ID: 21233400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR9 signaling through NF-κB/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells.
    Moreira D; Zhang Q; Hossain DM; Nechaev S; Li H; Kowolik CM; D'Apuzzo M; Forman S; Jones J; Pal SK; Kortylewski M
    Oncotarget; 2015 Jul; 6(19):17302-13. PubMed ID: 26046794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model.
    Hamzah J; Altin JG; Herringson T; Parish CR; Hämmerling GJ; O'Donoghue H; Ganss R
    J Immunol; 2009 Jul; 183(2):1091-8. PubMed ID: 19561111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity.
    Moreira D; Sampath S; Won H; White SV; Su YL; Alcantara M; Wang C; Lee P; Maghami E; Massarelli E; Kortylewski M
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33232304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer-induced immune suppression in the sentinel lymph node is effectively countered by CpG-B in conjunction with inhibition of the JAK2/STAT3 pathway.
    van Pul KM; Vuylsteke RJCLM; de Beijer MTA; van de Ven R; van den Tol MP; Stockmann HBAC; de Gruijl TD
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33046620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual TLR9 and PD-L1 targeting unleashes dendritic cells to induce durable antitumor immunity.
    Fernandez-Rodriguez L; Cianciaruso C; Bill R; Trefny MP; Klar R; Kirchhammer N; Buchi M; Festag J; Michel S; Kohler RH; Jones E; Maaske A; Vom Berg J; Kobold S; Kashyap AS; Jaschinski F; Dixon KO; Pittet MJ; Zippelius A
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37208130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
    Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
    Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.